Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Société Française de Greffe de Moelle study.
Bordigoni P, Esperou H, Souillet G, Pico J, Michel G, Lacour B, Reiffers J, Sadoun A, Rohrlich P, Jouet JP, Milpied N, Lutz P, Plouvier E, Cornu G, Vannier JP, Gandemer V, Rubie H, Gratecos N, Leverger G, Stephan JL, Boutard P, Vernant JP. Bordigoni P, et al. Among authors: gandemer v. Br J Haematol. 1998 Aug;102(3):656-65. doi: 10.1046/j.1365-2141.1998.00825.x. Br J Haematol. 1998. PMID: 9722290 Free article. Clinical Trial.
Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia.
Bellott R, Auvrignon A, Leblanc T, Pérel Y, Gandemer V, Bertrand Y, Méchinaud F, Bellenger P, Vernois J, Leverger G, Baruchel A, Robert J. Bellott R, et al. Among authors: gandemer v. Cancer Chemother Pharmacol. 2001;47(1):15-21. doi: 10.1007/s002800000206. Cancer Chemother Pharmacol. 2001. PMID: 11221955 Clinical Trial.
Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.
Perel Y, Auvrignon A, Leblanc T, Vannier JP, Michel G, Nelken B, Gandemer V, Schmitt C, Lamagnere JP, De Lumley L, Bader-Meunier B, Couillaud G, Schaison G, Landman-Parker J, Thuret I, Dalle JH, Baruchel A, Leverger G; Group LAME of the French Society of Pediatric Hematology and Immunology. Perel Y, et al. Among authors: gandemer v. J Clin Oncol. 2002 Jun 15;20(12):2774-82. doi: 10.1200/JCO.2002.07.300. J Clin Oncol. 2002. PMID: 12065553 Clinical Trial.
Economic evaluation of recombinant human granulocyte colony-stimulating factor in very high-risk childhood acute lymphoblastic leukemia.
Delorme J, Badin S, Le Corroller AG, Auvrignon AA, Auclerc MF, Gandemer V, Bordigoni P, Lamagnere JP, Demeocq F, Perel Y, Berthou C, Bauduer F, Pautard B, Vannier JP, Braguer D, Leblanc T, Leverger G, Baruchel A, Michel G. Delorme J, et al. Among authors: gandemer v. J Pediatr Hematol Oncol. 2003 Jun;25(6):441-7. doi: 10.1097/00043426-200306000-00004. J Pediatr Hematol Oncol. 2003. PMID: 12794521 Clinical Trial.
Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology.
Aladjidi N, Auvrignon A, Leblanc T, Perel Y, Bénard A, Bordigoni P, Gandemer V, Thuret I, Dalle JH, Piguet C, Pautard B, Baruchel A, Leverger G; French Society of Pediatric Hematology and Immunology. Aladjidi N, et al. Among authors: gandemer v. J Clin Oncol. 2003 Dec 1;21(23):4377-85. doi: 10.1200/JCO.2003.11.066. J Clin Oncol. 2003. PMID: 14645428
Maintenance therapy in childhood acute myeloid leukemia.
Perel Y, Auvrignon A, Leblanc T, Michel G, Vannier JP, Dalle JH, Gandemer V, Schmitt C, Mèchinaud F, Lamagnere JP, Piguet Ch, Couillaud G, Pautard B, Baruchel A, Leverger G; Group LAME; French Society of Pediatric Hematology and Immunology. Perel Y, et al. Among authors: gandemer v. Ann Hematol. 2004;83 Suppl 1:S116-9. doi: 10.1007/s00277-004-0850-2. Ann Hematol. 2004. PMID: 15124700 Clinical Trial.
Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group.
Perel Y, Auvrignon A, Leblanc T, Michel G, Reguerre Y, Vannier JP, Dalle JH, Gandemer V, Schmitt C, Méchinaud F, Lejars O, Piguet C, Couillaud G, Pautard B, Landman-Parker J, Thuret I, Aladjidi N, Baruchel A, Leverger G; French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group. Perel Y, et al. Among authors: gandemer v. Leukemia. 2005 Dec;19(12):2082-9. doi: 10.1038/sj.leu.2403867. Leukemia. 2005. PMID: 16121218 Clinical Trial.
Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children.
Dufourg MN, Landman-Parker J, Auclerc MF, Schmitt C, Perel Y, Michel G, Levy P, Couillault G, Gandemer V, Tabone MD, Demeocq F, Vannier JP, Leblanc T, Leverger G, Baruchel A. Dufourg MN, et al. Among authors: gandemer v. Leukemia. 2007 Feb;21(2):238-47. doi: 10.1038/sj.leu.2404495. Epub 2006 Dec 14. Leukemia. 2007. PMID: 17170721 Clinical Trial.
220 results